Mengis Capital Management Inc. Buys 124 Shares of Eli Lilly and Company (NYSE:LLY)

Mengis Capital Management Inc. lifted its holdings in Eli Lilly and Company (NYSE:LLYFree Report) by 1.7% in the 3rd quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 7,349 shares of the company’s stock after acquiring an additional 124 shares during the period. Eli Lilly and Company makes up approximately 0.8% of Mengis Capital Management Inc.’s portfolio, making the stock its 29th biggest position. Mengis Capital Management Inc.’s holdings in Eli Lilly and Company were worth $3,948,000 at the end of the most recent quarter.

Several other hedge funds also recently modified their holdings of LLY. Thompson Investment Management Inc. bought a new position in Eli Lilly and Company during the third quarter valued at about $27,000. Retirement Group LLC grew its stake in Eli Lilly and Company by 159.1% in the 2nd quarter. Retirement Group LLC now owns 57 shares of the company’s stock valued at $27,000 after buying an additional 35 shares in the last quarter. Cornerstone Planning Group LLC bought a new stake in Eli Lilly and Company during the 2nd quarter worth approximately $33,000. Legacy Financial Group LLC bought a new position in Eli Lilly and Company in the 3rd quarter worth about $35,000. Finally, Family CFO Inc purchased a new position in Eli Lilly and Company in the 3rd quarter worth approximately $40,000. Institutional investors own 81.38% of the company’s stock.

Insider Buying and Selling at Eli Lilly and Company

In related news, major shareholder Lilly Endowment Inc sold 1,180 shares of Eli Lilly and Company stock in a transaction on Tuesday, January 16th. The shares were sold at an average price of $645.60, for a total value of $761,808.00. Following the sale, the insider now owns 99,542,630 shares of the company’s stock, valued at approximately $64,264,721,928. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. In the last ninety days, insiders sold 195,055 shares of company stock worth $125,254,657. Company insiders own 0.13% of the company’s stock.

Wall Street Analyst Weigh In

LLY has been the topic of several recent research reports. Wells Fargo & Company increased their target price on shares of Eli Lilly and Company from $700.00 to $825.00 and gave the company an “overweight” rating in a report on Tuesday, February 6th. Morgan Stanley raised their price objective on Eli Lilly and Company from $763.00 to $805.00 and gave the company an “overweight” rating in a research note on Wednesday, February 7th. BMO Capital Markets boosted their target price on Eli Lilly and Company from $710.00 to $865.00 and gave the company an “outperform” rating in a research note on Wednesday, February 7th. StockNews.com upgraded Eli Lilly and Company from a “hold” rating to a “buy” rating in a research report on Friday, November 3rd. Finally, Deutsche Bank Aktiengesellschaft started coverage on shares of Eli Lilly and Company in a research report on Thursday, November 9th. They issued a “hold” rating and a $535.00 price objective on the stock. One research analyst has rated the stock with a sell rating, two have given a hold rating and seventeen have given a buy rating to the stock. Based on data from MarketBeat, the company has a consensus rating of “Moderate Buy” and an average target price of $621.81.

Read Our Latest Report on LLY

Eli Lilly and Company Stock Down 0.4 %

Shares of Eli Lilly and Company stock traded down $2.90 on Monday, reaching $737.26. The company’s stock had a trading volume of 2,927,781 shares, compared to its average volume of 3,414,614. The company has a market capitalization of $699.89 billion, a price-to-earnings ratio of 127.61, a P/E/G ratio of 2.08 and a beta of 0.32. The company has a quick ratio of 0.82, a current ratio of 1.05 and a debt-to-equity ratio of 1.59. Eli Lilly and Company has a 52 week low of $309.20 and a 52 week high of $745.70. The firm’s fifty day simple moving average is $620.02 and its two-hundred day simple moving average is $581.92.

Eli Lilly and Company (NYSE:LLYGet Free Report) last posted its earnings results on Tuesday, February 6th. The company reported $2.49 earnings per share for the quarter, beating the consensus estimate of $2.30 by $0.19. The company had revenue of $9.35 billion during the quarter, compared to analysts’ expectations of $8.95 billion. Eli Lilly and Company had a net margin of 15.36% and a return on equity of 50.78%. Eli Lilly and Company’s quarterly revenue was up 28.1% on a year-over-year basis. During the same period last year, the company posted $2.09 earnings per share. Equities analysts anticipate that Eli Lilly and Company will post 12.52 earnings per share for the current year.

Eli Lilly and Company Increases Dividend

The business also recently announced a quarterly dividend, which will be paid on Friday, March 8th. Shareholders of record on Thursday, February 15th will be given a dividend of $1.30 per share. This represents a $5.20 annualized dividend and a yield of 0.71%. The ex-dividend date is Wednesday, February 14th. This is an increase from Eli Lilly and Company’s previous quarterly dividend of $1.13. Eli Lilly and Company’s payout ratio is currently 77.93%.

About Eli Lilly and Company

(Free Report)

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. It offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; and Jardiance, Trajenta, and Trulicity for type 2 diabetes.

Featured Articles

Want to see what other hedge funds are holding LLY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Eli Lilly and Company (NYSE:LLYFree Report).

Institutional Ownership by Quarter for Eli Lilly and Company (NYSE:LLY)

Receive News & Ratings for Eli Lilly and Company Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eli Lilly and Company and related companies with MarketBeat.com's FREE daily email newsletter.